Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals Announces Equity Investment by Abbott Biotech Ventures Inc.

Alvine Pharmaceuticals Announces Equity Investment by Abbott Biotech Ventures Inc.

May 26, 2010

SAN CARLOS, Calif. – May 26, 2010 - Alvine Pharmaceuticals, Inc., a privately held clinical stage biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/inflammatory diseases, today announced that Abbott Biotech Ventures Inc., has joined Alvine’s current investors: Interwest Partners, Panorama Capital, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures in the company’s Series A Extension financing. The terms of the investment were not disclosed.

Brainshark, Inc.
Concert Pharmaceuticals, Inc.

Two of Flagship’s Portfolio Company CEOs Named Ernst & Young Entrepreneur Of The Year® 2010 Award Finalist

Two of Flagship’s Portfolio Company CEOs Named Ernst & Young Entrepreneur Of The Year® 2010 Award Finalist

May 20, 2010

Joe Gustafson, CEO of Brainshark, and Dr. Roger Tung, CEO of Concert Pharmaceuticals, have been named as finalists in this year's Ernst & Young Entrepreneur of the Year competition. Flagship congratulates both on their honor in being nominated for this prestigious award. Full text of the Ernst & Young press release follows:

Finalists for Ernst & Young Entrepreneur Of The Year® 2010 awards in New England announced

Ze-gen, Inc.

Ze-gen Welcomes David Robertson As Vice President of Technology

Ze-gen Welcomes David Robertson As Vice President of Technology

April 28, 2010

BOSTON--(BUSINESS WIRE)-- Ze-gen, Inc., a leading developer and integrator of advanced gasification technology to convert waste streams into synthesis gas, today announced the addition of David Robertson to the Ze-gen team. Mr. Robertson is joining Ze-gen as Vice President of Technology.

Mr. Robertson joins Ze-gen after a 30 year career with BP plc. He will be leading the technology development, project deployment, and operations activities at Ze-gen as they progress commercialization of their gasification process.

VisEn Medical, Inc.

VisEn Launches New Gastrosense™ 750 Fluorescence Imaging Agent

VisEn Launches New Gastrosense™ 750 Fluorescence Imaging Agent

March 25, 2010

Extends VisEn’s Leading Fluorescence Imaging Agent Portfolio to Enable Real Time Measurements of Gastric Motility and Related Drug Effects In Vivo

BEDFORD, MA (March 25, 2010)—VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new GastroSense™ 750 fluorescence agent for imaging gastric motility and related drug effects in vivo.

BG Medicine, Inc.

BG Medicine and Siemens Healthcare Diagnostics to Develop Galectin-3 Test for Siemens Automated Immunoassay Platforms

BG Medicine and Siemens Healthcare Diagnostics to Develop Galectin-3 Test for Siemens Automated Immunoassay Platforms

January 6, 2011

Waltham, MA—January 6, 2011. BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world’s largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization of a galectin-3 test for Siemens’ automated immunoassay platforms for clinical laboratories.

Receptos, Inc.

Receptos Announces License to Advance Structure-Based Drug Discovery for High-Value G-Protein Coupled Receptor (GPCR) Targets

Receptos Announces License to Advance Structure-Based Drug Discovery for High-Value G-Protein Coupled Receptor (GPCR) Targets

January 6, 2011

Deal with Ortho-McNeil-Janssen Pharmaceuticals, Inc. represents blueprint for technology sharing as a new paradigm emerges from Receptos for discovering best-in-class therapeutic drug candidates for GPCR targets

Receptos, Inc.

Receptos Announces Exclusive Collaboration with Lilly

Receptos Announces Exclusive Collaboration with Lilly

January 6, 2011

Collaborative efforts to focus on structure determination and lead generation for high-value G-protein Coupled Receptor (GPCR) target

Eleven Biotherapeutics, Inc.

Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development

Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development

January 6, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the appointment of Eric Furfine, Ph.D., as president of research and development. Dr. Furfine replaces Burt Adelman, M.D., who has served as the company’s interim president of research and development since its founding. Dr. Adelman will continue to serve as a scientific advisor to the company.

BG Medicine, Inc.

BG Medicine announces new publication on prognostic value of galectin-3 in heart failure patients

BG Medicine announces new publication on prognostic value of galectin-3 in heart failure patients

January 4, 2011

January 4, 2011 -- Waltham, MA, BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel diagnostics, today announced the publication* of a study exploring the predictive value of plasma galectin-3 levels in heart failure (HF) patients with reduced and preserved ejection fraction.

Adnexus Therapeutics

Former Portfolio Company Adnexus Therapeutics CEO, John Mendlein, Profiled by Xconomy.com as "Parallel Entrepreneur"

Former Portfolio Company Adnexus Therapeutics CEO, John Mendlein, Profiled by Xconomy.com as "Parallel Entrepreneur"

January 3, 2011

John Mendlein, former CEO of Flagship portfolio company Adnexus Therapeutics, was highlighted recently on Xconomy.com. Mendlein successfully led Adnexus to a $500M exit with its sale to Bristol-Myers Squibb in September of 2007.

John Mendlein, Biotech Exec With Surfer Look, Follows Winding Path as “Parallel Entrepreneur”

Luke Timmerman 1/3/11, Xconomy.com